ライフサイエンスコーパス: SGLT2 inhibitor

1 SGLT2 inhibitors protected against the risk of major adv

2 ucose with a sodium-glucose cotransporter 2 (SGLT2) inhibitor could improve insulin-mediated tissue g

3 hypoglycemic sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin and the insulin sensitize

4 iflozin, the sodium-glucose cotransporter 2 (SGLT2) inhibitor, on renal hemodynamics and tubular func

5 gliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor.

6 nt with the sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin reduced albuminuria in pa

7 Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of antidiabetic drugs.

8 g effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors are already established, guidance is n

9 Carbasugar sodium-glucose cotransporter 2 (SGLT2) inhibitors are highly promising drug candidates f

10 Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve glycaemia in patients with typ

11 gon release, sodium-glucose cotransporter 2 (SGLT2) inhibitors induce stimulation of endogenous gluco

12 Sodium-glucose cotransporter 2 (SGLT2) inhibitors lower glycemia by enhancing urinary gl

13 ering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk

14 eported with sodium-glucose cotransporter 2 (SGLT2) inhibitors.

15 2 diabetes, sodium-glucose cotransporter-2 (SGLT2) inhibitors are known to reduce glucose concentrat

16 Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozi

17 rofile, the sodium-glucose co-transporter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have b

18 gonists and sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce glycaemia and weight, and impro

19 Compared with other agents, SGLT2 inhibitors reduced body weight (mean difference, -

20 the efficacy and safety of canagliflozin, an SGLT2 inhibitor, with glimepiride in patients with type

21 el glucose lowering agent, empagliflozin, an SGLT2 inhibitor which targets the kidney to block glucos

22 ynthetic route towards some novel carbasugar SGLT2 inhibitors, featuring an underexploited, regiosele

23 he way towards the development of carbasugar SGLT2 inhibitors as potential antidiabetic/antitumor age

24 However, the clinical usage of carbasugar SGLT2 inhibitors has been underexplored, due to the leng

25 ealed the unexpected SAR of these carbasugar SGLT2 inhibitors, and enabled the discovery of a highly

26 ts), which provided data for seven different SGLT2 inhibitors.

27 Each SGLT2 inhibitor user was matched with three users of oth

28 The first SGLT2 inhibitors have been approved as a new class of an

29 However, SGLT2 inhibitors in clinical development inhibit only 30

30 ure and diabetic glomerular hyperfiltration, SGLT2 inhibitors may induce protective effects on the ki

31 Matched SGLT2 inhibitor (n=22 830) and other glucose-lowering dr

32 ecause of their unique glycosuric mechanism, SGLT2 inhibitors also reduce weight.

33 synthetic route towards some small-molecule SGLT2 inhibitors by a chemo- and diastereospecific palla

34 Our aim was to study the effects of SGLT2 inhibitor on circulating ZAG and ADI in nT2DM.

35 fraction may be mitigated by the actions of SGLT2 inhibitors to reduce blood pressure, body weight,

36 The benefits of SGLT2 inhibitors in heart failure may be mediated by the

37 of the potential cardiovascular benefits of SGLT2 inhibitors.

38 However, maximal doses of SGLT2 inhibitors fail to inhibit >50% of the filtered gl

39 Observations: The beneficial effect of SGLT2 inhibitors on heart failure cannot be explained by

40 way, sodium-related physiological effects of SGLT2 inhibitors and clinical correlates of natriuresis,

41 summarize the key pharmacodynamic effects of SGLT2 inhibitors and the clinical evidence that support

42 We aimed to establish the effects of SGLT2 inhibitors on cardiovascular events, death, and sa

43 ponsible for the cardioprotective effects of SGLT2 inhibitors remain incompletely understood.

44 ut not Sglt2-knockout mice, and injection of SGLT2 inhibitors prevented this binding.

45 rmacokinetic and pharmacodynamic profiles of SGLT2 inhibitors in clinical trials and examine possible

46 These data suggest net protection of SGLT2 inhibitors against cardiovascular outcomes and dea

47 accounts for the high kidney specificity of SGLT2 inhibitors.

48 ntify significant differences between use of SGLT2 inhibitors and use of other glucose-lowering drugs

49 ce that support the rationale for the use of SGLT2 inhibitors in patients with HF who have T2D.

50 rong rationale to expect benefit from use of SGLT2 inhibitors in patients with type 2 diabetes at hig

51 ed with other glucose-lowering drugs, use of SGLT2 inhibitors was associated with a decreased risk of

52 ed with other glucose-lowering drugs, use of SGLT2 inhibitors was associated with decreased risk of c

53 Patients were divided into new users of SGLT2 inhibitors and new users of other glucose-lowering

54 ular mortality and morbidity in new users of SGLT2 inhibitors versus new users of other glucose-lower

55 onsistent with data from clinical studies on SGLT2 inhibitors and provide a rationale for the mode of

56 iven by findings for empagliflozin (the only SGLT2 inhibitor for which data from a dedicated long-ter

57 of canagliflozin therapy compared with other SGLT2 inhibitors.

58 e discovery of a highly selective and potent SGLT2 inhibitor.

59 discovery of two highly selective and potent SGLT2 inhibitors, thereby paving the way towards the dev

60 tes and a broad cardiovascular risk profile, SGLT2 inhibitor use was associated with reduced cardiova

61 We treated db/db mice with a selective SGLT2 inhibitor JNJ 39933673.

62 ecursors was synthesized and tested as SGLT1/SGLT2 inhibitors using a cell-based fluorescence assay o

63 These data indicate that SGLT2 inhibitor elicits direct tubular effects in non-di

64 ge pancreatic and prostate cancers, and that SGLT2 inhibitors, currently in use for treating diabetes

65 e adenocarcinomas, and provide evidence that SGLT2 inhibitors block glucose uptake and reduce tumor g

66 nical practice guidelines now recommend that SGLT2 inhibitors with proven cardiovascular benefit be p

67 the GLP-1 receptor agonist exenatide and the SGLT2 inhibitor dapagliflozin with exenatide or dapaglif

68 blood pressure and glycaemic effects of the SGLT2 inhibitor dapagliflozin with placebo in patients w

69 thod is demonstrated by the synthesis of the SGLT2 inhibitor, canagliflozin (1a), from commercially a

70 hod was demonstrated by the synthesis of the SGLT2 inhibitor, canagliflozin.

71 The mechanisms by which the SGLT2 inhibitor empagliflozin increases LDL cholesterol

72 94% of the total SGLT2 inhibitor exposure time was for use of dapaglifloz

73 produced, it is important to understand why SGLT2 inhibitors inhibit <50% of the filtered glucose lo

74 nital tract infections were more common with SGLT2 inhibitors (odds ratios, 1.42 [CI, 1.06 to 1.90] a

75 clinical trials, large clinical trials with SGLT2 inhibitors are now investigating the potential use

76 f ongoing cardiovascular outcome trials with SGLT2 inhibitors.